JAK3 and extranodal nasal NK/T cell lymphoma: JAK3 mutations have been reported using next generation sequencing in natural killer/T-cell lymphoma (NKTCL) from cohorts in Singapore [17,18,19], Latin America (Mexico, Peru and Argentina) [20], Korea [21,22], Thailand, Japan [23] and France [24], which partly led to the constitutive phosphorylation of JAK3 [18,24], activation of JAK3/STAT signaling [17,20] and interleukin-independent NKTCL cell survival [21].